07:05:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-06-19 Årsstämma
2024-06-06 X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 Bokslutskommuniké 2023
2023-10-04 Split CRNA 30:1
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-22 Årsstämma
2023-04-21 X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 Extra Bolagsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-20 Årsstämma
2022-04-07 X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-03-18 X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 Årsstämma
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-07 Kvartalsrapport 2020-Q1
2020-04-30 X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 Årsstämma
2020-03-11 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-04-10 X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 Årsstämma
2019-02-14 Bokslutskommuniké 2018
2018-11-01 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-03 Kvartalsrapport 2018-Q1
2018-04-12 X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 Årsstämma
2018-02-15 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-05 Årsstämma
2017-02-16 Bokslutskommuniké 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-14 X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 Årsstämma
2015-06-23 X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 Årsstämma

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs idag under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.
2021-11-04 07:00:13
Oslo, Norway, 4 November 2021 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, today announces its third quarter 2021 results. Targovax's CEO will give
an online presentation and update on the clinical program to investors, analysts
and the press at 10:00 CET today (details below).

THIRD QUARTER HIGHLIGHTS

· Received acceptance of two posters to be presented at the Society for
Immunotherapy of Cancer (SITC) Annual Meeting in November

· Presented poster at European Society for Medical Oncology (ESMO)

· Received European Patent for ONCOS-102 in combination with chemotherapy

· Announced Dr Lone Ottesen's appointment as Chief Development Officer and Ola
Melin as Head of Manufacturing

POST-PERIOD HIGHLIGHTS

· In October, Dr. Erik Digman Wiklund was appointed as new Chief Executive
Officer. Dr. Wiklund has a strong scientific background in cancer research, and
intimate knowledge of the company and its technology having served as Chief
Business Officer and Chief Financial Officer of Targovax since 2017. Former CEO
Øystein Soug will remain with the company following the appointment of Dr.
Wiklund. Mr. Soug will act as a special advisor and also serve as interim CFO
providing important strategic and management continuum for the company.

KEY FIGURES

Amounts in NOK 3Q 2021 3Q 2020 9M 2021 9M 2020 FY 2020
thousands

Total operating - 34 - 624 624
revenues
Total operating -22 539 -22 073 -70 078 -81 652 -104 524
expenses
Operating -22 539 -22 039 -70 078 -81 028 -103 901
profit/loss
Net financial items -781 -718 -1 294 -1 089 -4 503
Income tax 11 73 42 220 277
Net profit/loss -23 309 -22 684 -71 330 -81 898 -108 126

Basic and diluted  -0.27  -0.30  -0.82  -1.10  -1.40
EPS (NOK/share)

Net change in cash -17 127 -23 808 -68 257 7 228 51 893
Cash and cash 71 192 101 465 122 321 70 429 70 429
equivalents start of
period
Cash and cash 54 064 77 657 54 064 77 657 122 321
equivalents end of
period

Erik Digman Wiklund, CEO commented: "Taking over the leadership of Targovax at a
time when we have demonstrated a clear signal of efficacy accompanied by a deep
biomarker data package for our lead candidate ONCOS-102, is a truly exciting
opportunity. The insights we have gained allow us to select the optimal
combination strategy for the next development step, as well as to design
innovative and differentiated second generation ONCOS vectors to shape our
platform for the future."

Presentation

We invite to a live webcast today at 10.00 CET. You can join the webcast
here (https://channel.royalcast.com/landingpage/hegnarmedia/20211104_11/). It
will be possible to ask questions during the presentation.

Reporting material

TRVX Q3
report.pdf (https://mb.cision.com/Public/17093/3446803/afeb113e438d4cce.pdf)

TRVX Q3
presentation.pdf (https://mb.cision.com/Public/17093/3446803/a025da7d0e3836c3.pd
f
)

The quarterly report and presentation are also available at the website
www.targovax.com (https://www.targovax.com/en/financial-reports/).

***

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax's
focus is to "activate the patient's immune system to fight cancer", thus
extending and transforming the lives of cancer patients. Targovax's pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company's product candidates are designed to harness the
patient's own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.